Sporadic Creutzfeldt-Jakob Disease in 2 Plasma Product Recipients, United Kingdom
Patrick Urwin, Kumar Thanigaikumar, James W. Ironside, Anna Molesworth, Richard S. Knight, Patricia E. Hewitt, Charlotte Llewelyn, Jan Mackenzie, and Robert G. Will
Author affiliations: University of Edinburgh Western General Hospital, Edinburgh, Scotland, UK (P. Urwin, J.W. Ironside, A. Molesworth, R.S. Knight, J. Mackenzie, R.G. Will); University Hospital Lewisham, London, UK (K. Thanigaikumar); National Health Service Blood and Transplant, London (P.E. Hewitt); National Health Service Blood and Transplant/Public Health England Epidemiology Unit, Cambridge, UK (C. Llewelyn)
Main Article
Table 2
Selected characteristics and clinical features of the 2 patients with sporadic Creutzfeldt-Jakob disease described in cases 1 and 2, United Kingdom, 2014*
Characteristic/clinical feature
|
Case 1
|
Case 2
|
Patient age, y/sex
|
64/F
|
64/F
|
Symptoms/signs
|
Ataxia, cognitive impairment, visual impairment, myoclonus
|
Somnolence/depression, dysphasia, cognitive impairment, myoclonus/ataxia
|
Magnetic resonance imaging |
+ |
+ |
Electroencephalogram |
+ |
Slow activity |
Cerebrospinal fluid 14–3–3 assay |
+ |
+ |
RT-QuIC
|
+
|
+
|
Genotype |
MM |
MM |
Diagnosis |
Definite sCJD |
Definite sCJD |
Duration |
3 mo |
7 mo |
|
Main Article
Page created: May 11, 2017
Page updated: May 11, 2017
Page reviewed: May 11, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.